REGENERON PHARMACEUTICALS, INC（REGN）の決算・業績分析
REGENERON PHARMACEUTICALS, INCの2025年有価証券報告書をAI分析。売上高$14.3B(+1.0%)。営業利益$3.6B。Health Care。
目次
REGENERON PHARMACEUTICALS, INCの2025年度 業績サマリー
REGENERON PHARMACEUTICALS, INC（証券コード: REGN）の2025年度決算・業績分析。売上高は$14.3B（前年比+1.0%）。営業利益は$3.6B（前年比-10.3%）。純利益は$4.5B（前年比+2.1%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
REGENERON PHARMACEUTICALS, INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue declined 24.3% YoY to $12.2B (XBRL), driven by reduced sales of key products like EYLEA HD and Dupixent (10-K).
- Operating income fell 47.0% YoY to $4.7B (XBRL), with operating margin remaining stable at 38.9% (XBRL).
- Net debt was -$1.1B (-0.2x EBITDA) (XBRL), reflecting strong liquidity despite a 46.3% YoY drop in net income to $4.3B (XBRL).
- Cash conversion cycle (CCC) extended to 229 days (XBRL), with receivables days at 170 and inventory days at 77 (XBRL).
REGENERON PHARMACEUTICALS, INCの売上高変化の要因
- •Total revenue declined 24.3% YoY to $12.2B (XBRL), down from $16.1B in FY2023 (XBRL). The drop is attributed to reduced sales of EYLEA HD, EYLEA, and Dupixent (10-K), as well as increased R&D and commercialization costs (10-K). Segment-specific revenue data is not provided in the XBRL or 10-K (XBRL). Over the past five years, revenue grew at a 20.6% CAGR (XBRL), but FY2024 marks a significant reversal in this trend.
REGENERON PHARMACEUTICALS, INCの営業利益変化の要因
- •Operating income fell 47.0% YoY to $4.7B (XBRL), with operating margin holding steady at 38.9% (XBRL). Net income declined 46.3% YoY to $4.3B (XBRL), driven by higher R&D expenses and commercialization costs (10-K). EBITDA increased 41.7% YoY to $5.1B (XBRL), reflecting cost discipline despite revenue declines. Net margin remained robust at 35.6% (XBRL).
REGENERON PHARMACEUTICALS, INCの事業リスクと対応
Heavy reliance on key products (EYLEA, EYLEA HD, Dupixent) exposes the company to revenue volatility if sales decline (10-K).
Reimbursement and coverage policy changes from payors could impact product sales (10-K).
Intense competition from superior or cost-effective alternatives may reduce market share (10-K).
Regulatory risks include potential approval revocation due to safety issues or clinical trial failures (10-K).
Manufacturing and supply chain constraints could delay product launches or clinical trials (10-K).
REGENERON PHARMACEUTICALS, INCの今後の見通し・業績予想
REGENERON PHARMACEUTICALS, INCの事業内容
Regeneron Pharmaceuticals, Inc. (REGN) is a biopharmaceutical company focused on developing and commercializing innovative therapies for serious medical conditions. Its revenue model relies on the sale of key products, including EYLEA, EYLEA HD, and Dupixent (10-K). The company faces risks related to product dependence, reimbursement policies, and competition (10-K). While segment-specific revenue data is unavailable (XBRL), the 10-K highlights reliance on these core products for revenue generation.
REGENERON PHARMACEUTICALS, INCのAI業績分析レポート（2024年度）
Regeneron Pharmaceuticals, Inc. (REGN) FY2024 Annual Report Analysis
Highlights
Business Overview
Regeneron Pharmaceuticals, Inc. (REGN) is a biopharmaceutical company focused on developing and commercializing innovative therapies for serious medical conditions. Its revenue model relies on the sale of key products, including EYLEA, EYLEA HD, and Dupixent (10-K). The company faces risks related to product dependence, reimbursement policies, and competition (10-K). While segment-specific revenue data is unavailable (XBRL), the 10-K highlights reliance on these core products for revenue generation.
Revenue Analysis
Total revenue declined 24.3% YoY to $12.2B (XBRL), down from $16.1B in FY2023 (XBRL). The drop is attributed to reduced sales of EYLEA HD, EYLEA, and Dupixent (10-K), as well as increased R&D and commercialization costs (10-K). Segment-specific revenue data is not provided in the XBRL or 10-K (XBRL). Over the past five years, revenue grew at a 20.6% CAGR (XBRL), but FY2024 marks a significant reversal in this trend.
Profitability Analysis
Operating income fell 47.0% YoY to $4.7B (XBRL), with operating margin holding steady at 38.9% (XBRL). Net income declined 46.3% YoY to $4.3B (XBRL), driven by higher R&D expenses and commercialization costs (10-K). EBITDA increased 41.7% YoY to $5.1B (XBRL), reflecting cost discipline despite revenue declines. Net margin remained robust at 35.6% (XBRL).
Balance Sheet Analysis
Equity ratio was 56.7% (XBRL), with total equity rising to $18.8B (XBRL) in FY2024. Long-term debt was $2.0B (XBRL), resulting in net debt of -$1.1B (-0.2x EBITDA) (XBRL). Cash reserves totaled $3.1B (XBRL), and the current ratio was 5.69x (XBRL), indicating strong liquidity. No geographic or segment-specific asset data is available (XBRL).
Cash Flow Analysis
Operating cash flow declined 29.6% YoY to $5.0B (XBRL), down from $7.1B in FY2023 (XBRL). Free cash flow (FCF) was $1.2B (XBRL), with $2.1B allocated to share repurchases (XBRL). No dividends were mentioned (XBRL). Investing cash flow was -$3.8B (XBRL), but CapEx details and acquisition activity are not disclosed (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 229 days (XBRL), driven by 170 days of receivables and 77 days of inventory (XBRL). Payables days were 18 days (XBRL), contributing to a 229-day CCC. Asset turnover was 0.37x (XBRL), indicating underutilized assets.
Risks
Outlook
Management expects future results to depend on the commercialization of EYLEA HD, EYLEA, and Dupixent (10-K), as well as R&D expenses and collaboration profits (10-K). No explicit forward-looking guidance is provided in the 10-K (10-K).
Health Careの企業一覧
REGENERON PHARMACEUTICALS, INCと同じ「Health Care」セクターの企業